Treatments for glioblastoma (GB) are critically insufficient. We aim to develop an efficient therapy based on a molecularly-specific-delivery of the extremely potent long-lived α particle 225Ac. Substance P (SP) binds neurokinin receptors NK1, overexpressed in GB. Recently, targeted therapies using 90Y- or 213Bi-labeled SPs have emerged as potent options but are either toxic or insufficient. Via 225Ac-SP intracranial delivery, we intend to longitudinally treat GB and eradicate disseminated brain tumors.
ABOU Diane;
GUERRERO-CAZARES H;
MINN Il;
POMPER Martin;
QUINONES-HINOJOSA Alfredo;
MORGENSTERN Alfred;
BACK Tom;
HOBBS Robert F.;
WAHL Richard;
SGOUROS George;
2014-08-27
SOC NUCLEAR MEDICINE INC
JRC88667
0161-5505,
http://jnumedmtg.snmjournals.org/cgi/content/meeting_abstract/55/1_MeetingAbstracts/393,
https://publications.jrc.ec.europa.eu/repository/handle/JRC88667,
| Name | Country | City | Type |
|---|
This document is only visible at the Commission level.
You are not authorized to publish or distribute it outside the European Commission.
This is a public document. You can share this publication.
Datasets
| ID | Title | Public URL |
|---|
Dataset collections
| ID | Acronym | Title | Public URL |
|---|
Scripts / source codes
| Description | Public URL |
|---|
Additional supporting files
| File name | Description | File type |
|---|